Literature DB >> 3065747

Interaction between transforming growth factor-alpha and c-Ha-ras p21 in progression of human gastric carcinoma.

T Yamamoto1, T Hattori, E Tahara.   

Abstract

The expression of TGF alpha and c-Ha-ras p21 was studied immunohistochemically in a total of 174 gastric carcinomas, comprising 27 early carcinomas and 147 advanced carcinomas. TGF alpha-immunoreactivity was detected in 7 (25.9%) of the 27 early carcinomas and in 110 (74.8%) of the 147 advanced carcinomas, the incidence being significantly different between the two (P less than 0.01). Out of the 67 c-Ha-ras p21 positive carcinomas, 59 (88.1%) showed TGF alpha-immunoreactivity synchronously. A significant positive correlation was observed between the grade of TGF alpha and incidence of c-Ha-ras p21-immunoreactivity in tumor cells (P less than 0.01). Furthermore, a good correlation was demonstrated between synchronous expression of TGF alpha and c-Ha-ras p21 and depth of tumor invasion (P less than 0.01). The incidence of synchronous expression of TGF alpha and c-Ha-ras p21 in metastatic tumors was significantly higher than that in primary tumors showing no lymphatic metastasis (P less than 0.01). Patients with carcinomas showing synchronous expression of TGF alpha and c-Ha-ras p21 had an extremely poorer prognosis than those without TGF alpha and c-Ha-ras p21. These results indicate that the synchronous expression of TGF alpha and c-Ha-ras p21 plays an important role in high malignancy of gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3065747     DOI: 10.1016/S0344-0338(88)80050-5

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Expression of transforming growth factor alpha in human tissues: immunohistochemical study and northern blot analysis.

Authors:  W Yasui; Z Q Ji; H Kuniyasu; A Ayhan; H Yokozaki; H Ito; E Tahara
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Preoperative staging of gastric cancer as precondition for multimodal treatment.

Authors:  A Sendler; H J Dittler; H Feussner; H Nekarda; E Bollschweiler; U Fink; H Helmberger; H Höfler; J R Siewert
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

Review 3.  Molecular biology and gastric carcinoma.

Authors:  P A Wright; G T Williams
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

Review 4.  Growth factors and oncogenes in human gastrointestinal carcinomas.

Authors:  E Tahara
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 5.  Pathologic prognostic factors for gastrointestinal cancer.

Authors:  T Ismail; M T Hallissey; J W Fielding
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

6.  Augmentation of 5-fluorouracil cytotoxicity by epidermal growth factor in a newly established human signet-ring cell carcinoma of the stomach in culture.

Authors:  K Aizawa; I Muto; S Suzuki; N Tanaka; H Yabusaki; S Tanaka; N Katayanagi; T Suzuki; O Tanaka; T Muto
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Expression of epidermal growth factor, transforming growth factor-alpha and their receptor genes in human gastric carcinomas; implication for autocrine growth.

Authors:  K Yoshida; E Kyo; T Tsujino; T Sano; M Niimoto; E Tahara
Journal:  Jpn J Cancer Res       Date:  1990-01

8.  Induction of growth factor-receptor and metalloproteinase genes by epidermal growth factor and/or transforming growth factor-alpha in human gastric carcinoma cell line MKN-28.

Authors:  K Yoshida; T Tsujino; W Yasui; T Kameda; T Sano; H Nakayama; T Toge; E Tahara
Journal:  Jpn J Cancer Res       Date:  1990-08

9.  Epidermal growth factor induces the expression of its receptor gene in human gastric carcinoma cell line TMK-1.

Authors:  K Yoshida; A Takanashi; E Kyo; M Ito; H Ito; M Niimoto; T Hattori; E Tahara
Journal:  Jpn J Cancer Res       Date:  1989-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.